key: cord-0976576-micqu8ri authors: Pang, Juan; Liu, Mingyao; Ling, Wenhua; Jin, Tianru title: Friend or Foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment date: 2021-01-06 journal: Obes Med DOI: 10.1016/j.obmed.2020.100312 sha: 7cb91fcd0bd96013d62f794879f8bec9135f8f20 doc_id: 976576 cord_uid: micqu8ri COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since WHO made the statement on March 11, 2020. The infection is causing a high mortality in old people, especially those with obesity, type 2 diabetes (T2D) or cardiovascular diseases (CVD). Extra cautions are needed in the treatment of those patients. The CVD drugs ACEIs and ARBs, as well as the T2D drugs GLP-1R agonists, were shown to activate angiotensin-converting enzyme 2 (ACE2) expression in experimental animals. Elevated ACE2 expression may accelerate virus entrance into the host cells during the infection for its replication. However, expression of the soluble ACE2, may neutralize the virus to limit the infection and replication. Given that obese, diabetes and CVD patients often take those medicines in the treatment and prevention of blood pressure and glucose elevation, it remains to be determined whether those medicines represent friend or foe in the treatment of COVID-19. We suggest that retrospective studies should be conducted to determine the exact impact of those medicines in obese, diabetic, or CVD patients who had COVID-19. Results obtained will provide guidance whether those drugs can be utilized in COVID-19 patients with obesity, diabetic, or CVD. Coronavirus Disease 2019 (COVID- 19) , which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since the statement made by WHO on March 11, 2020 . More than 61.5 million people have been infected to date and more than 1.4 million lives have been taken away. Although the pandemic may be under the control with effective vaccines following the global efforts, the high mortality in individuals with obesity, type 2 diabetes (T2D), and cardiovascular diseases (CVD) is currently a challenge in the fight against COVID-19 infection. The analysis of clinical characteristics of COVID-19 in China and elsewhere have clearly revealed that old people with chronic comorbidities have a higher risk for severe symptoms than younger individuals in the infection (1; 2). A recent study indicates that the diabetes drug metformin is able to reduce the mortality rate in the COVID-19 patients (3). Intensive investigations have been conducted in exploring the relationship between obesity and the severity of COVID-19 (4) (5) (6) . Here we would like to present a commentary on the use of the two categories of therapeutic agents in COVID-19 patients with metabolic disorders including obesity, T2D and CVD. Patients with hypertension are commonly treated with the renin angiotensin system (RAS) antagonists, such as angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the control of blood pressure. However, these drugs have been J o u r n a l P r e -p r o o f reported to increase the expression of angiotensin converting enzyme 2 (ACE2) (7; 8), which is recognized as the receptor of SARS-CoV-2 in the cell surface, especially the lung epithelial cells (8; 9) . Thus, there has been a speculation that this class of antihypertension drugs might facilitate the infection and replication of the virus (10; 11). On the other hand, some researchers believed that the expression may be a beneficial response in terms of limiting the lung injuries by the infection (12; 13) . Collectively, the exact impact of ACEIs and ARBs in the infection is still under debate. Here we present two lines of justifications supporting the hypothesis that those hypertension medicines may reduce the mortality in COVID-19 patients. As presented in Figure 1 , RAS system consists of two reciprocally constrained arms: one is for generation of angiotensin II (Ang II) from angiotensinogen by the enzymes renin and ACE; another is for degradation of Ang II to angiotensin 1-7 by the enzyme ACE2. Therefore, ACE2 plays a counter-regulatory role in the inhibition of RAS system by removing Ang II. It has been reported that ACE2 protected against the severe acute lung failure (14) . ACE2 was shown to be crucial in the prevention of the development of severe acute respiratory syndrome in the SARS-CoV infection (15) . Moreover, ACE2 generates angiotensin 1-7, which has activities including vasodilation, anti-hypertrophy and anti-inflammation (16) . Therefore, induction of ACE2 levels by the medicines, ACEIs or ARBs, may generate a protective effect in the COVID-19 patients by reduction of the severe respiratory symptoms risk. Conversely, Ang II has a negative feedback in the regulation of ACE2 activity by induction of TNF-α converting enzyme (TACE) leading to ACE2 cleavage ( Fig. 1 ) (17) . J o u r n a l P r e -p r o o f TACE, also known as metalloprotease 17 (ADAM17), is a major protease for ACE2 ectodomain shedding (18) . The cleavage happens between amino acids 716 and 741 near the predicted transmembrane domain and residue Lys 548 in the ectodomain (19) , which produces two types of soluble ACE2 (sACE2) with molecular mass of 105 kDa and 95 kDa. It is possible that the shedding ectodomain still possesses the capacity to bind coronavirus but does not mediate the virus entry into the host cell. It has been demonstrated that sACE2 efficiently blocked the association of SARS virus with its cellular receptor (20) , and averted the lung injuries (15) . COVID-19 virus replication can be abolished by a recombinant sACE2 protein fused to the Fc portion of immunoglobulin in vitro (21) . Consistently, the recombinant sACE2 protein has been employed as a potential therapeutic agent for COVID-19 (22; 23) . In healthy human subjects, plasma sACE2 level is very low (24) . However, the level can be significantly induced in patients who are taking ACEIs or ARBs (25; 26). When ACE2 was cardiac-specifically overexpressed in mice, serum sACE2 level can be increased approximately 20-fold (27) . These observations suggest that the level of extracellular sACE2 can be raised by ACEIs or ARBs, serving as potent decoy receptor for virus neutralization. ACEIs and ARBs may exhibit different activities in the induction of sACE2. In contrast to ACEIs which reduce the level of Ang II and hence deplete the substrate of ACE2, ARBs can promote Ang II accumulation in extracellular compartments towards ACE2, thus inducing the cleavage of ACE2 with increased production of sACE2. Overall, we agree with others that ACE2 based drugs represent a double-edged sword in coronavirus infection (28; 29) . Although it is an entry for coronavirus invasion, it plays a vital role in protection of the patients against severe tissue damage, especially in the lung. It China Medical Treatment Expert Group for C: Clinical Characteristics of Coronavirus Disease 2019 in China Obesity risk during collective quarantine for the COVID-19 epidemic Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity Gut microbiome dysbiosis and endotoxemia -Additional pathophysiological explanation for increased COVID-19 severity in obesity A multicenter consensus: A role of furin in the endothelial tropism in obese patients with COVID-19 infection Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury Angiotensin-converting enzyme 2 protects from severe acute lung failure A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2) ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking Angiotensin Converting Enzyme 2: A Double-Edged Sword Furin: A Potential Therapeutic Target for COVID-19 Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin The incretin hormone GLP-1 and mechanisms underlying its secretion The glucagon-like peptides Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein Moderate preventative effect with intraperitoneal liraglutide injection Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 -7)/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Receptor Agonists Play a Role? Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? -GLP-1 might play one too Animal models for COVID-19 Baric RS: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures Juan Pang is a recipient of China Scholarship Council (CSC). We thank Dr. Jianping Ye for his valuable comments and suggestions.